Novartis danced into a big week in the biopharma calendar with a trio of deals. The Swiss drugmaker is paying $250 million to renew its interest in a cytokine, dropping $185 million on two RNAi cardiovascular disease candidates and handing over $37.5 million to partner with an AI-enabled biotech.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,